Valuation: Capricor Therapeutics, Inc.

Market Cap 1.34B 1.17B 1.08B 1.01B 1.9B 127B 1.94B 12.99B 5.03B 62.35B 5.02B 4.91B 217B P/E 2026 *
-39x
P/E 2027 * -35.3x
Enterprise Value 1.34B 1.17B 1.08B 1.01B 1.9B 127B 1.94B 12.99B 5.03B 62.35B 5.02B 4.91B 217B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 10.9x
Free-Float
90.53%
Yield 2026 *
-
Yield 2027 * -
1 day+0.15%
1 week-21.82%
Current month-4.19%
1 month-19.14%
3 months-23.41%
6 months-20.06%
Current year-20.06%
1 week 23.04
Extreme 23.04
27.4
1 month 23.04
Extreme 23.04
30.93
Current year 21.06
Extreme 21.0601
36.82
1 year 4.3
Extreme 4.3
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
47.9
Manager TitleAgeSince
Chief Executive Officer 62 20/11/2013
Director of Finance/CFO 40 01/01/2018
Chief Tech/Sci/R&D Officer - 13/05/2025
Director TitleAgeSince
Chairman 70 01/11/2013
Director/Board Member 68 20/11/2013
Director/Board Member 79 20/11/2013
Date Insider Type Main position Quantity % Market Cap.
06-25Fiscal year

General Counsel

72,300 0.1248%
06-25Fiscal year

Chief Financial Officer

72,300 0.1248%
06-24Fiscal year

General Counsel

1,200 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+0.22%-21.82%+137.84%+382.64% 1.34B
+1.86%+3.38%+72.77%+131.31% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+1.44%+4.11%-12.64%-12.98% 23.75B
+1.29%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+1.93%+5.81%+40.51%-29.77% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
+0.75%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average +2.03%+4.06%+60.57%+166.70% 23.72B
Weighted average by Cap. +1.79%+6.44%+56.95%+133.52%

Financials

2026 *2027 *
Net sales 118M 104M 95.43M 88.92M 168M 11.23B 171M 1.15B 445M 5.51B 443M 434M 19.18B 122M 107M 98.87M 92.13M 174M 11.63B 177M 1.19B 461M 5.71B 459M 449M 19.87B
Net income -28.4M -24.94M -22.95M -21.39M -40.34M -2.7B -41.16M -276M -107M -1.33B -107M -104M -4.61B -48.17M -42.29M -38.93M -36.27M -68.41M -4.58B -69.8M -468M -181M -2.25B -181M -177M -7.82B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
01/07/26 $23.07 -4.19% 1,807,652
30/06/26 $24.08 +1.18% 1,858,849
29/06/26 $23.80 -9.98% 3,243,527
26/06/26 $26.44 -13.03% 5,489,477
25/06/26 $30.40 +3.02% 1,029,332
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
23.07USD
Average target price
53.60USD
Spread / Average Target
+132.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock